Journal article
A hepatitis C virus DNA vaccine encoding a secreted, oligomerized form of envelope proteins is highly immunogenic and elicits neutralizing antibodies in vaccinated mice
MG Masavuli, DK Wijesundara, A Underwood, D Christiansen, L Earnest-Silveira, R Bull, J Torresi, EJ Gowans, B Grubor-Bauk
Frontiers in Immunology | FRONTIERS MEDIA SA | Published : 2019
Abstract
Hepatitis C virus (HCV) persistently infects approximately 71 million people globally. To prevent infection a vaccine which elicits neutralizing antibodies against the virus envelope proteins (E1/E2) which are required for entry into host cells is desirable. DNA vaccines are cost-effective to manufacture globally and despite recent landmark studies highlighting the therapeutic efficacy of DNA vaccines in humans against cervical cancer, DNA vaccines encoding E1/E2 developed thus far are poorly immunogenic. We now report a novel and highly immunogenic DNA vaccination strategy that incorporates secreted E1 and E2 (sE1 and sE2) into oligomers by fusion with the oligomerization domain of the C4b-..
View full abstractGrants
Awarded by Hospital Research Foundation
Funding Acknowledgements
This research was supported by grants from the National Health and Medical Research Council (NHMRC) of Australia, the Australian Centrerfor Hepatitis and HIV Virology (ACH2), and a grant from The Hospital Research Foundation (THRF). MM is supported by a scholarship from The University of Adelaide, DW is supported by a fellowship from THRF.